Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Fulvestrant × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 56 Neoplasm Metastasis 10 Ovarian Neoplasms 9 Endometrial Neoplasms 7 Neoplasms 6 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neoplasms by Site 3 Hereditary Sensory and Autonomic Neuropathies 3 Breast Diseases 3 Recurrence 2 Melanoma 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Lobular 2 Breast Cancer Metastatic 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Malignant Neoplasms of Female Genital Organs 1 Lung Neoplasms 1 Locoregional Recurrence 1 Hormone Receptor Positive Breast Carcinoma 1 HR-positive, HER2-negative Breast Neoplasms 1 HR+/HER2- Breast Cancer 1

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡